Inceptor Bio is building a diversified cell therapy portfolio with differentiation that matters across multiple cell types including T cells, Macrophages, and Natural Killers.
Inceptor Bio’s CAR-T platform is based on a novel co-stimulatory domain platform, M-STIM, that generates expansion kinetics that are differentiated from the CAR-T therapies currently on the market.
Inceptor Bio’s CAR-M platform enhances the unique capabilities of macrophages to target and engulf cancer cells.
Inceptor Bio has platforms in the below effector cells:
CAR-T cells are engineered to identify and kill cancer cells. There are multiple CAR-T therapies that have earned FDA approval.
CAR-Macrophages have the ability to access solid tumors, survive in their hostile environment, selectively destroy cancer cells, and activate an adaptive immune response by presenting engulfed tumor material.
CAR-Natural Killer cells are engineered to identify and attack cancer. Safety (avoiding GvHd) and accessibility (allogeneic) are two strong advantages.